Aurinia Pharmaceuticals EV/EBIT AUPH

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2025.

Today, Oct 23, 2026: 12.3×
Peer median: 10.5×

Aurinia Pharmaceuticals' EV/EBIT is 12.3× as of Oct 23, 2026.

The median for 10 large drugmakers of a similar size is 10.5×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	12.3×	11.1×	20.1×
2025	21.5×	16.3×	47.8×

Against its peers

Companies in Drug Manufacturers - General nearest Aurinia Pharmaceuticals' size, closest first, today.

Company	EV/EBIT
AUPHAurinia Pharmaceuticals	12.3×
PBHPrestige Consumer Healthcare	14.5×
HRMYHarmony Biosciences	6.9×
NRIXNurix Therapeutics	7.1×
ANIPANI Pharmaceuticals	10.5×
PAHCPhibro Animal Health	11.7×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	7.6×
OGNOrganon	9.5×
LQDALiquidia	21.7×
ARQTArcutis Biotherapeutics	111×
Peer median	10.5×

Where Aurinia Pharmaceuticals ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Aurinia Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.